Nocturia Clinical Trial
Official title:
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia
The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.
Fedovapagon is a selective vasopressin V2 receptor (V2 receptor) agonist that is being
developed for the treatment of Nocturia.
The antidiuretic effect of V2 receptor stimulation in the kidneys is well established
through the use of the peptide agonist, desmopressin, which shows clinical benefit in
diabetes insipidus, primary nocturnal enuresis and Nocturia.
Nocturia, defined as the complaint that the individual has to wake at night one or more
times to void, is a common complaint and shows an age-dependent increase in both prevalence
and severity (number of Nocturnal Voids). It is the most bothersome symptom of benign
prostatic hypertrophy (BPH) and has been linked to an age-dependent loss in circadian
release of endogenous nocturnal vasopressin and consequent over production of urine at night
(Nocturnal Polyuria).
The purpose of this Phase IIb study is to determine the efficacy of different doses of
fedovapagon in reducing the number of times subjects with Nocturia void during the night
together with other parameters including increasing the time between going to bed and waking
to first void. By establishing the effective doses of fedovapagon on these clinical
endpoints, the data from this study will determine the most appropriate dose(s) of
fedovapagon for the treatment of Nocturia to be taken forward into further studies.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03623880 -
Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders
|
N/A | |
| Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
| Completed |
NCT02904759 -
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
|
Phase 3 | |
| Completed |
NCT02905682 -
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects
|
Phase 3 | |
| Completed |
NCT01684800 -
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women
|
Phase 2 | |
| Completed |
NCT01694498 -
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men
|
Phase 2 | |
| Completed |
NCT01520948 -
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
|
Phase 3 | |
| Completed |
NCT01222598 -
A Study of Minirin Melt in Patients With Nocturia
|
N/A | |
| Recruiting |
NCT04305743 -
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
|
Phase 4 | |
| Completed |
NCT01486706 -
Efficacy and Safety of Gabapentin in Treating Overactive Bladder
|
Phase 2/Phase 3 | |
| Completed |
NCT04528784 -
Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT05874375 -
UCon Treatment of Overactive Bladder (OAB) in Males
|
N/A | |
| Completed |
NCT01223937 -
Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients
|
Phase 3 | |
| Withdrawn |
NCT01018225 -
Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness
|
Phase 4 | |
| Completed |
NCT05222477 -
Abdominal Muscle Exercises on Nocturia and Sleep Quality in Women With Type 2 Diabetes
|
N/A | |
| Withdrawn |
NCT02961114 -
Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy
|
Phase 1/Phase 2 | |
| Completed |
NCT02440841 -
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon
|
Phase 1 | |
| Completed |
NCT02068560 -
The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion
|
N/A | |
| Completed |
NCT01357356 -
Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia
|
Phase 2/Phase 3 | |
| Completed |
NCT02151253 -
Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
|
Phase 2/Phase 3 |